AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02741271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/Prednisolone
Description: Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
Study NCT02741271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
Study NCT01502345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine/device combination for prevention of HFRS
Description: PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
Study NCT02241681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Peptamen 1.5
Description: Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.
Study NCT05997004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
Study NCT01436994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block and Replace
Description: The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
Study NCT01720940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous vancomycin infusion
Description: 24-hour continuous infusion of vancomycin
Study NCT01720940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermittent vancomycin infusion
Study NCT00520351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClearCare
Description: contact lens care system
Study NCT00520351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optifree Replenish
Description: contact lens care system
Study NCT01597895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc 150 mg BID x 5 days with food
Study NCT01597895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Boceprevir
Description: Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
Study NCT01597895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Telaprevir
Description: Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
Study NCT01927081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: discussion group
Description: Participants engage in discussions regarding issues related to coping with advanced cancer and pain
Study NCT01927081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: gentle exercise
Description: Patients learn gentle exercise and breathing techniques
Study NCT02268292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bicycle exercise
Description: All enrolled subjects received a scheduled twelve-week exercise program. A commercially available bicycle (Giant CS800, Taichung, Taiwan) with an indoor bicycle stand (Giant Cyclotron Mag, Taichung, Taiwan) was used as the home exercise training modality.
Study NCT02463903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET)
Description: The participants in the intervention group will receive a work book explaining the theme and home assignment as well as providing a brief summary of every group session. The group leader has a manual. Both work book and manual have been translated to Swedish and adjusted to patients with chronic heart failure.
Study NCT02233387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection with [18F] HX4 and PET imaging
Description: A standard clinical \[18F\]FDG PET-CT will be performed for the radiotherapy planning.~After a minimum time interval of 24 hours, baseline \[18F\]HX4 PET scans will be performed:~Based on the phase I trial1 444 MBq (12 mCi) \[18F\]HX4 is administrated via a bolus IV injection.~The first image acquisition is started together with the administration of \[18F\]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i
Study NCT04323410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cast immobilization
Description: Cast immobilisation is done using finger trap traction. The fractured forearm is splinted above elbow with dorsal cast without attempted reduction.
Study NCT04323410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneus pinning
Description: Reduction under fluoroscopic guidance and fixation using two crossing 1.6mm K-wires.
Study NCT01069601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Focetria (2x H1N1 vaccine with MF59 adjuvants)
Description: 7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
Study NCT02562001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outpatient active group
Description: active tDCS during 20 minutes before Lokomat training for outpatients
Study NCT02562001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outpatient placebo group
Description: placebo tDCS during 20 minutes before Lokomat training for outpatients
Study NCT02562001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inpatient active group
Description: active tDCS during 20 minutes before Lokomat training for inpatients
Study NCT02562001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inpatient placebo group
Description: placebo tDCS during 20 minutes before Lokomat training for inpatients
Study NCT02576080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Study NCT02576080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surveillance
Description: The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan.
Study NCT04387435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A change or titration in the current or frequency settings of the VNS therapy system.
Description: The study treatment involves changing the output current or frequency of the default device settings in a FDA approved device for VNS therapy. The proposed frequency changes in this study are within the FDA approved output current and frequency levels.
Study NCT01709487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
Study NCT02567123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Study NCT00922064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECT
Description: ECT series consisting of 6 to 14 ECTs
Study NCT01215591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gradual weaning from Nasal CPAP in preterm neonates
Description: Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
Study NCT00198718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate)
Study NCT03389204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL THERAPY
Description: EXERCISES AND EDUCATION TO FOLLOWING AFTER DISCHARGE PHYSICAL TREATMENT
Study NCT01799733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LWT+AM BWL
Description: One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
Study NCT01799733 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EWT+PM BWL
Description: One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
Study NCT01165814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tramadol
Study NCT03361956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 tablet orally.
Study NCT03361956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablet orally.
Study NCT03361956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA (ETV or TDF)
Description: Participants will receive NA (ETV or TDF) tablet orally as per approved label.
Study NCT03361956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NA (ETV or TDF)
Description: Participants will receive NA (ETV or TDF) tablet orally as per approved label.
Study NCT00410410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept (ABA)
Description: Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57 (ABA 30/\~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months
Study NCT00410410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months
Study NCT00410410 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: abatacept
Description: \~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued
Study NCT02793063 — intervention group
Intervention type: OTHER
Intervention: Web-based Survey
Description: This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
Study NCT01308281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI with IVUS guidance
Description: Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
Study NCT01308281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI without IVUS guidance
Description: Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
Study NCT01708876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-mefloquine
Study NCT01708876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study NCT01708876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
Study NCT05004818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol
Description: GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol
Study NCT05004818 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
Study NCT01436994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dose Titration
Description: The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
Study NCT01436994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbimazole
Description: Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
Study NCT01436994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propylthiouracil
Description: 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
Study NCT01436994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroxine
Description: 25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
Study NCT02488434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fertile chip
Description: a new method for sperm selection on ivf cycles by using microchannel system.
Study NCT02920905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds.
Study NCT02920905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atracurium
Description: Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds.
Study NCT02920905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mg sulphate
Description: Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds.
Study NCT04775446 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data entered in a secure computer database
Study NCT02768896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Patients will walk naturally with EEG measuring brain waves
Study NCT02768896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual stimuli
Description: Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
Study NCT02768896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory stimuli
Description: Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
Study NCT02768896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual and auditory stimuli
Description: Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
Study NCT03955653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral artey access
Description: We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention
Study NCT03580265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser phototherapy device with low level laser
Description: The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.
Study NCT03580265 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laser phototherapy device with low level laser
Description: The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.
Study NCT03441425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unexpected death
Study NCT01412944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150mg
Description: secukinumab 150mg (2 injections per dose)
Study NCT01412944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 10mg/kg i.v. regimen
Description: secukinumab 10mg/kg i.v. regimen
Study NCT03363282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygium Excision
Description: Pterygium excision is the first step for repair
Study NCT02546284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenzilumab
Study NCT04147715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration
Study NCT04147715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral administration
Study NCT04147715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for oral administration
Study NCT04147715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Solution for oral administration
Study NCT04147715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Tablet for oral administration
Study NCT02112903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated vortioxetine IR tablet, 20 mg
Study NCT02112903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine MR capsule 20 mg (pH 5.5)
Study NCT02112903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine MR capsule 20 mg (pH 6.0)
Study NCT02112903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine MR capsule 20 mg (pH 7.0)
Study NCT04988945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Procedure of TACE will be standardized.
Study NCT04988945 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
Study NCT04988945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)
Study NCT04988945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
Study NCT01004081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB021
Description: BID orally for 28 days
Study NCT01004081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB021
Description: TIW orally for 28 days
Study NCT01004081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane (Aromasin)
Description: Daily in tablet form for 28 days
Study NCT03786289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human serum albumin/erythropoietin fusion protein
Description: Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1